Greener Gases 

Keck Medicine of USC is phasing out one of the most commonly used — and environmentally toxic — anesthetics for its surgeries, desflurane.

The discontinuation of desflurane is part of a universitywide effort to re-examine both USC’s and Keck Medicine of USC’s impact on climate change and to implement healthier, sustainable solutions whenever possible.

The operating room is one of the biggest — if not the biggest — waste generators in any hospital, says Arash Motamed, medical director for Keck Main Perioperative Operations and Keck Medicine of USC Sustainability.

“They’re very resistant to degradation; they stay in that environment for many years,” says Motamed, an associate professor and vice chair of clinical operations for the department of anesthesiology at the Keck School of Medicine of USC.

In June, the Association of Anesthetists noted the inconvenient truth about anesthetics.

It cited research showing that anesthetics are responsible for 0.1% of the world’s carbon emissions. At the hospital level, inhaled anesthetics make up more than 5% of acute hospital carbon emissions and 50% of perioperative emissions.

Anesthetics in the atmosphere

During a surgery with anesthetics, a patient breathes in an anesthetic gas, which circulates through the body and keeps the person unconscious. After the operation, the anesthetics are turned off, the concentration in the body decreases and the patient regains consciousness.

Keck’s operating rooms have three primary anesthetics, Motamed says. Each achieves similar effects but has different drawbacks.

Desflurane is very quick to come on and very quick to come off — that’s why people love it. But it’s expensive and horrible for the environment.

Aren Nercisian, anesthesiologist at Keck Medicine of USC

“Desflurane is very quick to come on and very quick to come off — that’s why people love it,” says Aren Nercisian, an anesthesiologist at Keck Medicine of USC. “But it’s expensive and horrible for the environment.”

Desflurane is the most commonly used. Yet, studies show desflurane is so harmful to the environment that an eight-hour surgery causes as much damage to the atmosphere as driving a car from Los Angeles to Maine.

“The contribution to emissions is huge,” said Howard Hu, holder of the Flora L. Thornton Chair in Preventive Medicine and chair and professor of population and public health sciences at the Keck School of Medicine of USC. “That insight became a clarion call for us to do something about it.”

In its own call to action on pollution reduction, the California Society of Anesthesiologists noted that desflurane lingers the longest of any anesthetic — 14 years — in the atmosphere’s lowest layer, the troposphere, just above the Earth’s surface. On the other hand, sevoflurane remains in the troposphere for just over a year while isoflurane lingers for 3.2 years.

Helping the environment, cutting costs

Global warming potential (GWP) is a way to quantify the amount that an agent contributes to global warming over a period of time. Nercisian, who leads sustainability efforts for the anesthesiology department at Keck Medicine of USC, explains that GWP measures how much energy the emission of 1 ton of a gas will absorb over a given period, relative to the emissions of 1 ton of carbon dioxide.” The larger the GWP, the more it warms the Earth compared to carbon dioxide. The GWP of carbon dioxide is 1.

Desflurane has a 20 times higher global warming potential than sevoflurane, Nercisian says.

Desflurane has the highest global warming potential — 2,540 — compared with sevoflurane, which has a GWP of 130.

The triple aim of a health system should be improving patient experience, improving the health of the population and reducing the cost of health care … sustainable delivery of care should be the fourth aim.

Arash Motamed

The three also differ in cost. Desflurane tends to be the most expensive. And so far, no studies have indicated whether one is worse for patients than the others.

“There’s never been a study to prove that you have better outcomes with sevoflurane vs. desflurane vs. isoflurane,” Nercisian says. “Though some agents have specific advantages.”

Keck Medicine of USC has not ordered more desflurane in the past year.

“According to Institute for Healthcare Improvement, the triple aim of a health system should be improving patient experience, improving the health of the population and reducing the cost of health care,” Motamed says. “Howard Hu, chair of Population and Public Health Sciences at USC, says that sustainable delivery of care should be the fourth aim. I couldn’t agree more.”

The post Greener Gases appeared first on USC News.

Greener Gases 

Science/Technology

Greener Gases 

Keck Medicine of USC is curbing the environmental impacts of anesthesia in operating rooms — and saving money 

December 12, 2022

Grayson Schmidt

Keck Medicine of USC is phasing out one of the most commonly used — and environmentally toxic — anesthetics for its surgeries, desflurane.

The discontinuation of desflurane is part of a universitywide effort to re-examine both USC’s and Keck Medicine of USC’s impact on climate change and to implement healthier, sustainable solutions whenever possible.

The operating room is one of the biggest — if not the biggest — waste generators in any hospital, says Arash Motamed, medical director for Keck Main Perioperative Operations and Keck Medicine of USC Sustainability.

“They’re very resistant to degradation; they stay in that environment for many years,” says Motamed, an associate professor and vice chair of clinical operations for the department of anesthesiology at the Keck School of Medicine of USC.

In June, the Association of Anesthetists noted the inconvenient truth about anesthetics.

It cited research showing that anesthetics are responsible for 0.1% of the world’s carbon emissions. At the hospital level, inhaled anesthetics make up more than 5% of acute hospital carbon emissions and 50% of perioperative emissions.

Anesthetics in the atmosphere

During a surgery with anesthetics, a patient breathes in an anesthetic gas, which circulates through the body and keeps the person unconscious. After the operation, the anesthetics are turned off, the concentration in the body decreases and the patient regains consciousness.

Keck’s operating rooms have three primary anesthetics, Motamed says. Each achieves similar effects but has different drawbacks.

Desflurane is very quick to come on and very quick to come off — that’s why people love it. But it’s expensive and horrible for the environment.

Aren Nercisian, anesthesiologist at Keck Medicine of USC

“Desflurane is very quick to come on and very quick to come off — that’s why people love it,” says Aren Nercisian, an anesthesiologist at Keck Medicine of USC. “But it’s expensive and horrible for the environment.”

Desflurane is the most commonly used. Yet, studies show desflurane is so harmful to the environment that an eight-hour surgery causes as much damage to the atmosphere as driving a car from Los Angeles to Maine.

“The contribution to emissions is huge,” said Howard Hu, holder of the Flora L. Thornton Chair in Preventive Medicine and chair and professor of population and public health sciences at the Keck School of Medicine of USC. “That insight became a clarion call for us to do something about it.”

In its own call to action on pollution reduction, the California Society of Anesthesiologists noted that desflurane lingers the longest of any anesthetic — 14 years — in the atmosphere’s lowest layer, the troposphere, just above the Earth’s surface. On the other hand, sevoflurane remains in the troposphere for just over a year while isoflurane lingers for 3.2 years.

Helping the environment, cutting costs

Global warming potential (GWP) is a way to quantify the amount that an agent contributes to global warming over a period of time. Nercisian, who leads sustainability efforts for the anesthesiology department at Keck Medicine of USC, explains that GWP measures how much energy the emission of 1 ton of a gas will absorb over a given period, relative to the emissions of 1 ton of carbon dioxide.” The larger the GWP, the more it warms the Earth compared to carbon dioxide. The GWP of carbon dioxide is 1.

Desflurane has a 20 times higher global warming potential than sevoflurane, Nercisian says.

Desflurane has the highest global warming potential — 2,540 — compared with sevoflurane, which has a GWP of 130.

The triple aim of a health system should be improving patient experience, improving the health of the population and reducing the cost of health care … sustainable delivery of care should be the fourth aim.

Arash Motamed

The three also differ in cost. Desflurane tends to be the most expensive. And so far, no studies have indicated whether one is worse for patients than the others.

“There’s never been a study to prove that you have better outcomes with sevoflurane vs. desflurane vs. isoflurane,” Nercisian says. “Though some agents have specific advantages.”

Keck Medicine of USC has not ordered more desflurane in the past year.

“According to the Institute for Healthcare Improvement, the triple aim of a health system should be improving patient experience, improving the health of the population and reducing the cost of health care,” Motamed says. “Howard Hu, chair of Population and Public Health Sciences at USC, says that sustainable delivery of care should be the fourth aim. I couldn’t agree more.”

The post Greener Gases  appeared first on USC Today.

New research focuses on cells’ building blocks, aging and stress

REDIRECT 8052

USC News *
New Research on Cells’ Building Blocks, Aging and Stress

Foundation grants support newly published research at the intersection of stress responses, aging and cellular structure and function.

Body Copy *
A recent study led by Assistant Professor of Gerontology Ryo Sanabria has identified a key protein that helps regulate the actin cytoskeleton, a scaffold of proteins within cells that makes their proper structure and function possible.

A review of genes both in the worm C. elegans and in human cells published in the journal Aging Cell revealed that the protein BET-1 promotes the proper function of actin, the protein that makes up the building blocks of the cytoskeleton. Overexpression of the gene for BET-1 appears to preserve actin function at later ages and improve health and lifespan in worms, according to the study.

Many of the cellular processes that depend on the actin cytoskeleton – from cell division to recycling damaged parts of the cell – deteriorate during aging and exposure to stress as the cytoskeleton breaks down. However, the regulatory mechanisms involved in preservation of cytoskeletal form and function are not well-understood, Sanabria said. With the cytoskeleton being necessary for numerous cellular functions as well as maintaining its very shape, understanding its regulation and how well it responds to stressors over time could shed light on many aging-related illnesses.

How stress and aging affect cells

A large part of Sanabria’s research interest is the intersection between stress and aging, including how organisms respond to stress, how stress impacts aging, and how organisms respond to stress at the cellular level. Stressors that affect organisms at the cell level can include heat, oxidation, infection, caloric restriction, and more.

“My lab has studied stress responses in three areas: the endoplasmic reticulum, which acts as a ‘factory’ for proteins, lipids, and other molecules within the cell; the mitochondria, where cells’ energy is produced; and the actin cytoskeleton, which helps cells keep or change their shape as needed,” Sanabria said. “Each of these systems has unique ways to respond to stress and maintain their health and function.”

Exposure to stress can be detrimental to cellular health and fitness, Sanabria explained, and thus cells have adapted cellular stress responses that mitigate damage associated with stress exposure. Cellular stress mechanisms decline during aging, making older organisms more sensitive to stress; hyperactivating stress responses can promote resilience and improve general health and longevity, they added.

“When you’re stressed, what’s your capacity to bounce back? The more you can recover from a stressor, the healthier you are, but with aging there is less response and recovery,” Sanabria explained. “But if you take a young person’s stress resilience and give it to an older individual, will they be healthier?”

New gifts support research on cells and stress

Sanabria’s quest to understand how stress and aging impact cellular structures, including the actin cytoskeleton, have been recognized with recent grants supporting their work from the Larry L. Hillblom Foundation, the Glenn Foundation for Medical Research/American Federation for Aging Research, and the Navigage Foundation.

The Hillblom Start-Up Research Grant will provide Sanabria a total of $210,000 over a three-year period to study how the actin cytoskeleton interacts with cells’ energy-producing mitochondria during stress and aging. The organization’s Start-Up grants were designed to help newer scientists begin their independent research careers. Sanabria arrived at the USC Leonard Davis School as an assistant professor in 2021 following a postdoctoral fellowship at UC Berkeley.

Sanabria also received a 2022 Junior Faculty Research Grant from the Glenn Foundation for Medical Research/American Federation for Aging Research in support of their work regarding stress and aging, especially in the endoplasmic reticulum. An organelle known for producing proteins, lipids and other molecules, the endoplasmic reticulum’s unfolded protein response is an important mechanism in preserving healthy protein structure in the face of toxic stress. The $125,000 grant supports Sanabria’s research into how hyperactivating this protective response in specific neurons within the brain can affect health and longevity, which could help identify which neurons are responsible for sensing stress and coordinating the body’s response to it.

In addition, Sanabria has received a $100,000 award from the Navigage Foundation to translate their studies into Alzheimer’s disease. Since they have found that promoting stress resilience is a potential method to increase longevity, the next question is whether it can also be used as a vehicle to combat age-related diseases, Sanabria said. With the support of the Navigage Foundation, Sanabria is investigating whether those that have higher risks for Alzheimer’s Disease had inherently lower capacity to deal with stress and whether increasing stress resilience can actually mitigate the risk – and even slow the progression – of Alzheimer’s disease.

“Large-scale genetic screens identify BET-1 as a cytoskeleton regulator promoting actin function and life span” appeared online in Aging Cell on November 20, 2022. First authors included Gilberto Garcia and Maxim Averbukh of the USC Leonard Davis School and Raz Bar-Ziv of UC Berkeley. Additional authors included Naibedya Dutta, Darius Moaddeli, Toni Castro Torres, Athena Alcala, Sally Hoang, an d Max A. Thorwald of the USC Leonard Davis School; Hanlin Zhang, Wudi Fan, C. Kimberly Tsui, and Erica A. Moehle of UC Berkeley; Nirmalya Dasgupta and Peter D. Adams of the Sanford Burnham Prebys Medical Discovery Institute; and Ophir Shalem of the University of Pennsylvania.

Additional funding for this study came from National Institutes of Health grants T32AG052374 and R01 AG071861, Larry L. Hillblom Foundation Fellowships 019-A-023 and 2020-A-018-FEL, National Institute on Aging grants F32AG069388 and R00AG065200, and National Institute of General Medical Sciences grant 1DP2GM137416-01.

The post New research focuses on cells’ building blocks, aging and stress appeared first on USC News.

USC works with Polaris Dawn to study in-flight space medicine

REDIRECT 8033
https://keck.usc.edu/usc-works-with-polaris-dawn-to-study-in-flight-space-medicine/
Story Headline and Deck – USC News *

USC works with Polaris Dawn to study in-flight space medicine

Researchers from the Keck School of Medicine of USC have designed a study, to be conducted on board the upcoming Polaris Dawn mission, that tests a new way to collect X-rays in outer space.
Body Copy *
Today’s spaceflights typically last a few days to a few months, so onboard medical treatment is mostly limited to first aid. But researchers are increasingly exploring new terrain–known as in-flight space medicine–that will be critical for maintaining astronauts’ health during longer missions, such as the 21-month roundtrip to Mars.

Polaris Dawn, the first of three missions in the Polaris Program, is pursuing an array of new frontiers in space. Estimated to launch no earlier March 1, 2023, its crew will aim to achieve the highest-ever orbit of Earth and attempt the first-ever commercial spacewalk. They will also spend up to five days conducting more than 38 studies of human health in space, including a Keck School of Medicine of USC-led effort to study a new approach to X-ray imaging onboard.

“Modern X-ray equipment isn’t practical to send into space because of its significant mass and electricity requirements,” said John Choi, MD, PhD, a resident physician in interventional radiology at the Keck School of Medicine of USC and the leader of the project. “But in order to do true clinical medicine in space during a mission–in-flight space medicine–we’re going to need radiology.”

Ultrasound is the primary diagnostic imaging method currently used in space because ultrasound equipment is relatively portable and does not require much power. But it cannot identify certain life-threatening medical issues, such as a blood clot in a major artery of the heart, lungs or brain.

For that reason, Choi and his colleagues believe that X-ray imaging and radiology–in addition to other medical capabilities and specialties such as surgery, anesthesia and emergency medicine–are crucial for effectively responding to medical emergencies in space. They are now exploring an innovative method that could allow clinicians to use the ambient radiation in space (natural radiation that is always present) to collect X-ray images with minimal equipment.

“In space, we know there’s more ionizing radiation than on Earth,” Choi said. “Can we take advantage of that radiation as a source that allows us to capture an image?”

Harnessing radiation in space

To answer that question, Choi and his team are leveraging technology from a simpler form of X-ray equipment than modern-day digital detectors: film. Because of its lower mass and power requirements, using this simpler equipment to absorb radiation for image generation could eliminate the practical problems with sending equipment into space.

In analog X-ray film imaging, a special “intensifying screen” converts radiation into visible light, which can then be developed on film. The researchers are sending a piece of this intensifying screen into space to test whether there is enough ambient radiation to cause the screen to glow.

Choi and his team are assembling the materials needed to conduct the experiment and the researchers are writing instructions for the Polaris Dawn crew to use when conducting the experiment onboard.

Enhancing health on Earth

The experiment, known as a “proof of principle,” is just the first step to establish whether ambient radiation in space is sufficient to generate X-ray images. If successful, researchers will then need to prove that they can conduct clinically meaningful X-ray exams using the new method.

A technological breakthrough could also offer helpful insights for X-rays on Earth, such as a way to collect images with less radiation. In addition to its goal of advancing human health in space, the Polaris Dawn mission seeks to gain scientific knowledge that could improve medical care closer to home.

“The mission profile of Polaris Dawn affords us some great opportunities to expand our collective knowledge about the human body in space and associated applicability here on Earth,” said Jared Isaacman, mission commander of Polaris Dawn. “Our science and research agenda will enhance the body of knowledge for future long-duration spaceflight which will take us back to the Moon and on to Mars; as well as progress our knowledge and understanding for humankind here on Earth.”

About this research

Choi’s co-investigators are Robert Ryu, professor and chair of the Department of Radiology, Keck School of Medicine of USC; Scott E. Fraser, provost professor of biological sciences and biomedical engineering, stem cell biology and regenerative medicine, Keck School of Medicine of USC and director of science initiatives for USC; and Amran Asadi, a medical engineer at SpaceX.

Funding for this research was provided by the University of Southern California, and the Department of Radiology of the Keck School of Medicine of USC.

The post USC works with Polaris Dawn to study in-flight space medicine appeared first on USC News.

USC Viterbi team develops ‘heart attack on a chip’

REDIRECT 8051

Saving Lives: Heart Attack On A Chip

Story Headline and Deck – USC News *
Saving Lives: Heart Attack On A Chip

Megan McCain and postdoc Megan Rexius-Hall have engineered a microscale model that might one day serve as a testbed for personalized heart drugs
Body Copy *
Megan McCain has always enjoyed building and fixing things. She also has long been fascinated by cells in the human body and how they work together to achieve important tasks, like how the heart pumps blood.

As a postdoctoral researcher at the Wyss Institute for Biologically Inspired Engineering at Harvard University, McCain combined these passions to engineer microscale models that can replicate myocardial structure and function, known as “heart on a chip.”

Now, the USC Viterbi associate professor of biomedical engineering, and stem cell biology and regenerative medicine and postdoctoral researcher Megan Rexius-Hall have developed a so-called “heart attack on a chip.” The device could one day serve as a testbed to develop new heart drugs and even personalized medicines.

“Our device replicates some key features of a heart attack in a relatively simple and easy to use system,” said McCain, whom the MIT Technology Review recognized in 2014 as one of the world’s top innovators under 35. “This enables us to more clearly understand how the heart is changing after a heart attack. From there, we and others can develop and test drugs that will be most effective for limiting the further degradation of heart tissue that can occur after a heart attack.”

McCain, the Chonette Early Career Chair and a self-proclaimed “cardiac tissue engineer,” and Rexius-Hall detail their findings in a recently released article in the journal Science Advances titled “A Myocardial Infarct Border-Zone-On-A-Chip Demonstrates Distinct Regulation of Cardiac Tissue Function by an Oxygen Gradient.” The National Heart, Lung, and Blood Institute and the American Heart Association (AHA) supported their research.

Other co-authors include Natalie Khalil, a USC Viterbi Ph.D. student in biomedical engineering; Sean Escopete and Sarah Parker of the Smidt Heart Institute at Cedars-Sinai Medical Center; and Xin Li, Jiayi Hu, Hongyan Yuan of the Department of Mechanics and Aerospace Engineering at Southern University of Science and Technology, China.

America’s No. 1 killer

Coronary heart disease is America’s No. 1 killer. In 2018, 360,900 Americans succumbed to it, making heart disease responsible for 12.6% of all deaths in the United States, according to the AHA.

Severe coronary heart disease can cause a heart attack, which accounts for much of that pain and suffering. Heart attacks occur when fat, cholesterol and other substances in the coronary arteries severely reduce the flow of oxygen-rich blood to part of the heart. Between 2005 and 2014, an average of 805,000 Americans per year had heart attacks.

Even if a patient survives one, over time they can become increasingly fatigued, enervated and sick; some even die due to heart failure. That’s because heart cells don’t regenerate like other muscle cells. Instead, immune cells appear at the site of injury, some of which can be harmful. Additionally, scarring develops that weakens the heart and the amount of blood it can pump.

This entire process is known as “adverse remodeling.” However, scientists don’t completely understand it, especially how heart cells in the healthy and injured parts of the heart communicate with each other and how and why they change after a heart attack.

McCain and Rexius-Hall believe their heart attack on a chip can shed some light on those mysteries.

“Fundamentally, we want to have a model that can lead to a better understanding of heart attack injury,” Rexius-Hall said.

Heart attack on a chip

The heart attack on a chip is literally built from the ground up. At the base is a 22-millimeter-by-22-millimeter square microfluidic device slightly larger than a quarter – made from a rubber-like polymer called PDMS – with two channels on opposing sides through which gases flow. Above that sits a very thin layer of the same rubber material, which is permeable to oxygen. A micro layer of protein is then patterned on the top of the chip, “so that the heart cells align and form the same architecture that we have in our hearts,” McCain said. Finally, rodent heart cells are grown atop the protein.

To mimic a heart attack, gas with oxygen and gas without oxygen is released through each channel of the microfluidic device, “exposing our heart on a chip to an oxygen gradient, similar to what really happens in a heart attack,” McCain said.

Because the microfluidic device is small, clear, and easy to view on a microscope, McCain added, it also allows researchers to observe in real time functional changes that sometimes happen in the heart after an attack, including an arrythmia, or an irregular heartbeat, and contractile dysfunction, or decreases in the contraction strength of the heart. In the future, researchers could make the model more complex by adding immune cells or fibroblasts, the cells that generate the scar after a heart attack.

By contrast, researchers cannot watch changes to heart tissue in real time with animal models. Additionally, traditional cell culture models uniformly expose heart cells to high, medium or low levels of oxygen, but not a gradient. That means they cannot mimic what really happens to damaged heart cells in the so-called border zone after a heart attack, Rexius-Hall said.

Added McCain: It is very exciting and rewarding to envision our device having a positive impact on patient lives in the near future, especially for heart attacks, which are extremely prevalent.”

The post USC Viterbi team develops ‘heart attack on a chip’ appeared first on USC News.

Can tech billionaires make prescription drugs more affordable?

REDIRECT 8048
https://priceschool.usc.edu/news/mark-cuban-amazon-pharmacy-drug-costs/
Story Headline and Deck – USC News *
Head: Can tech billionaires make prescription drugs more affordable?

Deck: Another big industry is being targeted for disruption. USC experts discuss the significance of Mark Cuban and Jeff Bezos launching online pharmacies as Americans pay high costs for prescription drugs.

Body Copy *
Takeaways:

Mark Cuban Cost Plus Drug Company offers lower prices by cutting out middlemen, whose pricing practices make generics more expensive, according to USC research.
Tech leaders have long wanted to enter healthcare, which is ripe for disruption and a huge market opportunity.
Online pharmacies still aren’t great for delivering drugs that need to be kept cold.
Americans who can’t afford prescription drugs may have a pair of unlikely allies: billionaires Mark Cuban and Jeff Bezos.

The two tech entrepreneurs, who made their riches disrupting retail, media and other markets, now have their sights set on healthcare. Both have launched online pharmacies claiming to sell drugs at lower and transparent prices.

Their entry into the pharmaceutical industry comes as Americans pay more for prescription drugs than people in other countries. For example, pharma firm AbbVie charged nearly double for blood cancer drug Imbruvica in the U.S. as compared to Australia and countries in Europe, according to the U.S. House Committee on Oversight and Reform. It’s an issue that has harmed many patients – who often can’t afford the treatments they need – and frustrated lawmakers, who haven’t succeeded in moderating drug costs.

“I think that part of what we’re seeing with these entrants is that policy is taking too long and it’s been ineffective in reducing what we, as a society, spend on drugs,” noted Karen Van Nuys, a health and finance expert at USC Schaeffer Center for Health Policy and Economics, which is a partnership between the USC Price School and the School of Pharmacy.

“There is a lot of excess spending and room to cut costs because intermediaries create a lot of waste,” she explained. “In the absence of strong policy, we are seeing a lot of innovation in the private sector to eliminate that waste.”

Cost Plus cuts out the pharmaceutical middlemen

Earlier this year, Cuban launched the Mark Cuban Cost Plus Drug Company, a wholesaler that sells generic drugs at prices lower than traditional retailers. The firm can offer lower rates, in large part, by not engaging with the health insurance system, avoiding middlemen and their markups.

The realm of pharmaceutical middlemen is an area where Van Nuys has done extensive research. She recently co-authored research showing how insurers and pharmacy benefit managers (PBMs) deploy pricing practices that cause consumers to overpay for generics.

In a tactic called “spread pricing,” for example, PBMs reimburse pharmacies one price when a beneficiary fills a prescription, while charging the health plan a higher price and pocketing the difference. Neither the pharmacy nor the health plan knows what the other side was charged.

“That doesn’t happen in the Mark Cuban system because there’s no distinction between what’s being paid to the pharmacy and what’s being charged to the health plan. There’s no PBM in the middle, taking a giant chunk out of it,” Van Nuys said.

One notable example is Imatinib, a drug prescribed to patients with specific forms of leukemia, a blood cell cancer. Cost Plus offers the drug for $14.40, whereas consumers buying it through insurance elsewhere could pay hundreds of dollars in co-payments, Van Nuys noted.

Cost Plus pricing model is similar to Costco’s

Cost Plus charges a flat 15% margin on top of their acquisition costs, plus pharmacist and delivery fees. The pricing model is a bit like Costco, the wholesale retail giant, said Arvind Bhambri, an associate professor of management and organization at the USC Marshall School of Business. Instead of always trying to charge the highest price they can, both firms start with the cost that they incur and just have a fixed markup, he noted.

“You’re not always sure that what you’re buying at Costco is going to be the lowest price that you can find anywhere,” Bhambri said. “But what you are very sure about is that you’re not being gouged.”

Healthcare has long been in the crosshairs of technology leaders because the size of the market is too big to ignore, Bhambri said. It’s unlikely, then, that the motivations of tech gurus are entirely altruistic, even if they pitch their ventures as a social benefit.

“Because healthcare is so inefficient and fragmented, there is an opportunity to both cut down on costs and still create a profitable company,” Bhambri said. It’s become a win-win. It has a social impact, plus it’s a good business to be in.”

Amazon Pharmacy and Cost Plus seek to disrupt the industry

Bezos’ Amazon Pharmacy isn’t as innovative as Cuban’s Cost Plus, in that Amazon still deals with health insurance and PBMs, Van Nuys said. Amazon Prime members can compare drug prices across pharmacies online and pay with insurance or Amazon Pharmacy’s discount card, which cuts up to 80% off drug prices. Much like its e-commerce business, the company offers free two-day delivery for Amazon Pharmacy purchases.

Amazon – which has subsidiaries in e-commerce, grocery stores, film production, cloud computing and more – looks for industries that have high margins and inefficient supply chains, Bhambri said. Amazon will typically come in, cut costs and price low enough to ensure that it is cheaper than alternatives that are equally convenient.

It remains to be seen whether Cost Plus and Amazon Pharmacy will meaningfully disrupt the pharmaceutical industry. One initial problem with both solutions, Van Nuys noted, is that they rely on mail order delivery, which isn’t great for drugs like insulin that need to be refrigerated.

“The Cost Plus Drugs model works well for inexpensive generic drugs that are straightforward to ship,” she said. “We don’t yet have good solutions for drugs like insulin that require special handling, or for really expensive drugs that aren’t affordable without insurance. We need to come up with creative solutions for those segments as well.”

Suggested social media post (wording that appears with your story on Facebook or Twitter). Ideally 140-250 characters. Include Facebook/Twitter handles of involved schools/units/professors as appropriate.
Mark Cuban and Jeff Bezos’ Amazon have launched online pharmacies offering drugs at lower and transparent prices. USC experts discuss the significance of their entry into the pharmaceutical market as Americans pay high costs for drugs. LINK

The post Can tech billionaires make prescription drugs more affordable? appeared first on USC News.

USC receives $10.5 million to develop cutting edge machine learning approaches in cancer research

REDIRECT 8044
Bokie Muigai
Author’s Email muigai@usc.edu
Author’s Department
PPHS
Is this story embargoed? *
No
URL of story on your school/unit website *
https://keck.usc.edu/artificial-intelligence-in-health-usc-researchers-receive-10-5-million-to-develop-cutting-edge-machine-learning-approaches-in-cancer-research/
Story Headline and Deck – USC News *
Artificial Intelligence in Health: USC Researchers receive $10.5 million to develop cutting edge machine learning approaches in cancer research
Body Copy *
The National Cancer Institute has awarded $10.5 million to the Division of Biostatistics at the Department of Population and Public Health Sciences at the Keck School of Medicine of USC. The Research Program Project Grant (P01) will enable researchers to develop statistical methods aimed at uncovering new risk-factors associated with cancer by drawing upon datasets of several cancer studies. The significance of the award is not only its highly competitive nature, but the allocation of funds towards the development of complex methods being applied to multiple sources of integrated data–rarely is a Program Project Grant awarded from the National Institutes of Health for solely statistical methodology research.

This incubator is co-led by James Gauderman, PhD, Chair of the Biostatistics Division, and Kimberly Siegmund, PhD, biostatistics expert in cancer modeling. The project aims to address some of the major problems faced in cancer research regarding vast data. The data are ‘big’ in terms of the large number of participants in epidemiological and clinical studies, as well as varying measures being collected across different investigations. The program will develop novel statistical methods to integrate large volumes of health, genomic, and exposure data to provide an opportunity for the discovery of genetic associations and genomic-by-exposure interactions related to cancer risk.

“We expect that the methods we develop and their corresponding applications to large ongoing studies will provide new insights into complex biological processes as well as discoveries of novel associations important for cancer risk, prognosis, and/or treatment” explains Gauderman. The first 5-year cycle of this program focused on colorectal cancer, including a study with over 130,000 subjects. Prior studies have produced a rich spectrum of potential biomarkers allowing for a better understanding of the disease and its prognosis. The renewal of the grant broadens the focus to also include breast, ovarian, and prostate cancer, with the potential to include other types of cancer. “What is exciting, is that there are many new technologies that allow us to measure what is happening inside our cells, and we are collecting those measurements on cancer cells,” shares Siegmund, an expert in statistical analysis and machine learning of epigenetic data in human disease. “So now, we are trying to create statistical methods to answer questions about how the cancer cells are behaving.”

This initiative is a collaborative effort that brings together numerous investigators with unique intellectual knowledge, interests, and experience from large-scale cancer epidemiology studies. This includes a recent nation-wide study of prostate cancer in African American men led by Chris Haiman, ScD, Chair of the Division of Epidemiology and Genetics. The grant also includes the Multi-ethnic Cohort established in 1993, with over 215,000 participants in Los Angeles counties and Hawaii. It is comprised of a diverse cohort including African American, Asian American, Caucasian, Hispanic, and Native Hawaiian participants. “We saw a need to bring together a number of people to the same table to discuss this new exciting data being collected, and explore how we can integrate genetics, environmental factors and a variety of omics measures,” explains Gauderman. “There is real utility in thinking about how to integrate data from multiple sources to examine aspects that were not anticipated by any one study alone.”

The researchers intend for their methods to be widely used throughout the field of cancer epidemiology. Similarly, another component of this study involves the development of statistical models into user-friendly software packages. It has been important to the research team to develop methods that will reach downstream users. “We are contributing to the software ecosystem by facilitating translation to other data sets–so that anyone can mimic what we are doing, to their own data,” affirms Siegmund. In this manner, their methods will be applicable to genetic epidemiology studies investigating not only cancer but many other traits.

Aims of the Program
1. Develop statistical analysis and machine learning methods that integrate big data to identify novel cancer risk factors.
2. Apply these statistical methods to various cancer studies to discover new biological insights. This in turn will lead to predictive models to inform targeted cancer interventions, such as screening programs aimed at recommended lifestyle changes.
3. Share user-friendly software tools with the broader scientific community ensuring the methods developed are widely available to apply to a wide range of data.

The Research Program Project Grant (P01) supports broadly based, integrated, multi-project research programs that have a major scientific objective or common theme. The National Cancer Institute awarded $10.5 million to the Division of Biostatistics of the Department of Population and Public Health Sciences, Keck School of Medicine of USC. The grant will enable researchers to develop statistical methods aimed at uncovering new risk-factors associated with cancer.

The post USC receives $10.5 million to develop cutting edge machine learning approaches in cancer research appeared first on USC News.

USC Norris Cancer Hospital earns top teaching hospital award for 2nd year in a row

USC Norris Cancer Hospital earns Leapfrog Top Teaching Hospital award for second year in a row
Top Teaching Hospital — final 2022
Photo by: Chris Shinn
National designation recognizes the hospital for outstanding quality and safety
LOS ANGELES — The Leapfrog Group, a national hospital watchdog organization, has named USC Norris Cancer Hospital a 2022 Top Teaching Hospital.

“This prestigious national honor, which highlights a hospital’s achievements in patient safety and quality, is one of the most competitive awards a hospital can receive,” said Marty Sargeant, MBA, CEO of USC Norris Cancer Hospital and Keck Hospital of USC. “I am proud of our efforts to maintain the highest standards of care.”

This is the second year in a row the hospital has won a Top Teaching Hospital award.

To qualify for the Top Hospitals distinction, hospitals must rank highest among peers on the Leapfrog Hospital Survey, which assesses the quality of patient care across many areas of hospital performance, including practices for safe surgery and preventing patient risks.

Over 2,200 hospitals nationwide were considered for a Top Hospital award, which recognized hospitals in four categories: children’s, general, rural and teaching.

A total of 115 hospitals were selected as Top Hospitals, including 58 Top Teaching Hospitals.

USC Norris Cancer Hospital is part of the USC Norris Comprehensive Cancer Center, which is part of Keck Medicine of USC. The National Cancer Institute (NCI) has designated the cancer center as one of the nation’s 51 comprehensive cancer centers, a select group of institutions providing leadership in cancer treatment, research, prevention and education.

To see the full list of institutions honored as 2022 Top Hospitals, please visit https://www.leapfroggroup.org/ratings-reports/top-hospitals.

The post USC Norris Cancer Hospital earns top teaching hospital award for 2nd year in a row appeared first on USC News.

It takes two: Research synergy links L.A. biomedical pillars

REDIRECT 8012

school/unit website *
https://keck.usc.edu/it-takes-two-research-synergy-links-l-a-biomedical-pillars/
Story Headline and Deck – USC News *
It takes two: Research synergy links L.A. biomedical pillars

Team science takes on a new dimension with Children’s Hospital Los Angeles and the Keck School of Medicine of USC
Body Copy *
For the Keck School of Medicine of USC and Children’s Hospital Los Angeles, there’s no shortage of common ground.

With robust collaboration, the two L.A. medical mainstays are united by nearly 60 research programs supported by external grants, the lion’s share from the National Institutes of Health and other federal funders. Projects foster therapeutic advances, patient care innovation and community wellness. These include major efforts that tackle some of the most challenging problems in human health — battling cancer, manufacturing the latest cell therapies to fight incurable disease, boosting COVID-19 vaccination rates in underrepresented L.A. communities and preventing obesity in Latino youth.

The institutions share a commitment to conducting leading-edge biomedical investigations, improving health outcomes for underserved populations and speeding new advances from the proverbial lab bench to the patient’s bedside.

The tightly knit alliance benefits health for people of all ages. Connecting CHLA and the Keck School of Medicine opens the way for researchers to find complementary resources and interdisciplinary teammates across both.

“When one investigator at one site has a burning question, they can cross over to seek expertise in how to approach that question,” said Pat Levitt, PhD, chief scientific officer, vice president and director of the Saban Research Institute and Simms/Mann Chair in Developmental Neurogenetics at CHLA, who is also W.M. Keck Provost Professor in Neurogenetics at USC. “It’s a natural bridge, for instance, from CHLA’s disease-focused basic and translational research to the Keck School of Medicine’s fundamental work on understanding disease processes.”

The faculty at CHLA, which ranks among the nation’s top 10 children’s hospitals, all hold appointments at the Keck School of Medicine, which is home to eight departments that rank top 10 in NIH funding in their fields. Together, the two research and academic powerhouses — independent of each other — make a bigger difference than either could make alone.

Both institutions play vital roles serving the diverse L.A. community. CHLA is a safety net pediatric hospital, with 70% of patients on subsidized healthcare or lacking insurance. Faculty from the Keck School of Medicine staff Los Angeles County + USC Medical Center, the largest single provider of health care in the county. As such, both institutions emphasize studies to address the health challenges of communities that are underserved and experience disparities in outcomes.

Several initiatives backed by federal grants exemplify a partnership with impact exceeding the sum of its parts.

Fighting cancer across the lifespan

USC Norris Comprehensive Cancer Center stands among the original eight such centers to receive the National Cancer Institute’s highest designation in 1971, and remains an innovative leader in the cancer field. The USC Norris $34 million Cancer Center Support Grant from the NCI supports cutting-edge cancer research and collaborations that span USC and CHLA.

Like many other diseases, cancer is understood to find its roots early along in development — as far back as the womb. So fully integrating oncology research between the two institutions has been a priority.

“To really understand cancer and other disorders of humankind, we have to think about developmental biology,” said Alan Wayne, M.D., director of Children’s Hospital Los Angeles Cancer & Blood Disease Institute and associate director for pediatric oncology at USC Norris Comprehensive Cancer Center. “In that regard, the kind of close collaboration you see between basic, translational, population and clinical scientists across campuses — and across the age span — is going to make a tremendous difference.”

Innovative therapies, innovative infrastructure

Wayne’s own research pushes forward CAR T cell therapy, a groundbreaking strategy that enhances the patients’ own immune cells to target cancer. These investigations — and many others across USC and CHLA — will get a boost from another joint venture: establishing a state-of-the-art facility for manufacturing such cellular treatments.

CHLA and the Keck School of Medicine (in partnership with Keck Medicine of USC and USC Norris cancer center) are on the cusp of opening a current good manufacturing practice facility for cellular treatments, part of the joint USC/CHLA Translational Cell Therapy Program.

“Cells have evolved for a million and a half years,” said Tom Buchanan, M.D., the Keck School of Medicine’s Bernard J. Hanley Chair in Medicine and vice dean of research. “It makes sense to take advantage of that evolution to fix things, so we’re setting up one sophisticated facility where people can use the same basic methodologies and work with each other, while targeting an array of diseases.”

The capacity to make treatments will accelerate translation of research into clinical trials. In addition to CAR T cells, potential products could be engineered tissue to address blindness, bone and cartilage injury, gastrointestinal disorders and even diabetes.

“These therapies have the potential to reverse, and in some cases prevent, conditions that have been considered irreversible,” Wayne said. “The facility is expected to have a massive impact.”

The drive from scientific discovery to health solution

Supporting the sort of studies that would be the testing grounds for cellular therapies are an important aspect of the Southern California Clinical and Translational Science Institute (SC CTSI). Backed by a $50 million NIH grant, the collaboration bands together the Keck School of Medicine, CHLA and the L.A. County Department of Health Services.

“Clinical trials are important across all populations,” said Buchanan, director of SC CTSI. “It’s crucial that we move from findings to real-world impact.”

The institute focuses on turning science into health solutions for the city’s diverse communities by providing researchers with funding, expertise, training and facilities. It provides backing for studies designed to benefit everyone from infants to elders, testing everything from treatment protocols to care delivery improvements to community interventions.

Health equity is often an area of concentration. Take, for example, the CTSI-associated Consortium for Pediatric Cellular Immunotherapy. Through the consortium, a CHLA-Keck School of Medicine contingent led by Wayne joins forces with four other leading biomedical centers. Part of its agenda is to expand access to the newest treatments, and increase clinical trial participation, among children in underserved communities.

Promoting protection in those hardest-hit by the pandemic

SC CTSI also launched a multimedia initiative that brought scientifically sound, culturally grounded messages to people in certain majority Latino and Black neighborhoods. VaccinateLA, a joint project of CHLA and the Keck School of Medicine funded by the W. M. Keck Foundation, made a major impact in East and South L.A.

Respectively, Latino and Black people in zip codes where VaccinateLA was active had immunization rates of 82% and 78%, compared to 66% and 58% in similar populations countywide.

Outreach from CHLA pediatricians was essential in reaching parents worried about their kids, according to VaccinateLA co-leader Lourdes Baezconde-Garbanati, PhD, MPH, the Keck School of Medicine’s associate dean for community initiatives and the SC CTSI’s associate director for community outreach and engagement.

“CHLA has been a major catalyst, and really important to our credibility in the communities we focus on,” she said.

A vision for healthy adulthood among Latinos, starting in childhood

Baezconde-Garbanati, a tenured professor of population and public health sciences at the Keck School of Medicine, also co-leads a regional initiative dedicated to making a difference in Hispanic health tomorrow, by laying the foundation with today’s youth.

The recently established Southern California Center for Chronic Health Disparities in Latino Families and Children was initiated by co-leader Michael Goran, PhD, program director for diabetes and obesity at CHLA’s Saban Research Institute and professor of pediatrics at the Keck School of Medicine.

The community-engaged, obesity-fighting project is funded by a $24.5 million award from the NIH. It has already shown dividends, growing into a wider consortium encompassing all of Southern California.

As with other collaborations between CHLA and the Keck School of Medicine, the power of that teamwork seems to add together one and one to make so much more than two.

“We’ve been able to kind of merge our worlds and bring a lot of different resources,” Baezconde-Garbanati said. “This has created something that just would not have existed with any one of us going it alone.”

The post It takes two: Research synergy links L.A. biomedical pillars appeared first on USC News.